These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 23165261)

  • 1. Down syndrome: the brain in trisomic mode.
    Dierssen M
    Nat Rev Neurosci; 2012 Dec; 13(12):844-58. PubMed ID: 23165261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the cause of mental retardation in Down syndrome: extrapolation from full and segmental trisomy 16 mouse models.
    Galdzicki Z; Siarey R; Pearce R; Stoll J; Rapoport SI
    Brain Res Brain Res Rev; 2001 Apr; 35(2):115-45. PubMed ID: 11336779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The "Down syndrome critical region" is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome.
    Belichenko NP; Belichenko PV; Kleschevnikov AM; Salehi A; Reeves RH; Mobley WC
    J Neurosci; 2009 May; 29(18):5938-48. PubMed ID: 19420260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of allelic differences in Down syndrome.
    Roper RJ; Hawley L; Goodlett CR
    Prog Brain Res; 2020; 251():29-54. PubMed ID: 32057311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trisomy for the Down syndrome 'critical region' is necessary but not sufficient for brain phenotypes of trisomic mice.
    Olson LE; Roper RJ; Sengstaken CL; Peterson EA; Aquino V; Galdzicki Z; Siarey R; Pletnikov M; Moran TH; Reeves RH
    Hum Mol Genet; 2007 Apr; 16(7):774-82. PubMed ID: 17339268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down syndrome: from understanding the neurobiology to therapy.
    Gardiner K; Herault Y; Lott IT; Antonarakis SE; Reeves RH; Dierssen M
    J Neurosci; 2010 Nov; 30(45):14943-5. PubMed ID: 21068296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trisomy 21 and early brain development.
    Haydar TF; Reeves RH
    Trends Neurosci; 2012 Feb; 35(2):81-91. PubMed ID: 22169531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consequences of trisomy 21 for brain development in Down syndrome.
    Russo ML; Sousa AMM; Bhattacharyya A
    Nat Rev Neurosci; 2024 Nov; 25(11):740-755. PubMed ID: 39379691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mouse models of Down syndrome: gene content and consequences.
    Gupta M; Dhanasekaran AR; Gardiner KJ
    Mamm Genome; 2016 Dec; 27(11-12):538-555. PubMed ID: 27538963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular and cellular mechanisms elucidating neurocognitive basis of functional impairments associated with intellectual disability in Down syndrome.
    Rachidi M; Lopes C
    Am J Intellect Dev Disabil; 2010 Mar; 115(2):83-112. PubMed ID: 20441388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mouse models of cognitive disabilities in trisomy 21 (Down syndrome).
    Roubertoux PL; Carlier M
    Am J Med Genet C Semin Med Genet; 2010 Nov; 154C(4):400-16. PubMed ID: 20981769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential gene expression studies to explore the molecular pathophysiology of Down syndrome.
    Antonarakis SE; Lyle R; Chrast R; Scott HS
    Brain Res Brain Res Rev; 2001 Oct; 36(2-3):265-74. PubMed ID: 11690624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down Syndrome Developmental Brain Transcriptome Reveals Defective Oligodendrocyte Differentiation and Myelination.
    Olmos-Serrano JL; Kang HJ; Tyler WA; Silbereis JC; Cheng F; Zhu Y; Pletikos M; Jankovic-Rapan L; Cramer NP; Galdzicki Z; Goodliffe J; Peters A; Sethares C; Delalle I; Golden JA; Haydar TF; Sestan N
    Neuron; 2016 Mar; 89(6):1208-1222. PubMed ID: 26924435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasoactive intestinal peptide in the brain of a mouse model for Down syndrome.
    Hill JM; Ades AM; McCune SK; Sahir N; Moody EM; Abebe DT; Crnic LS; Brenneman DE
    Exp Neurol; 2003 Sep; 183(1):56-65. PubMed ID: 12957488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trisomy of Erg is required for myeloproliferation in a mouse model of Down syndrome.
    Ng AP; Hyland CD; Metcalf D; Carmichael CL; Loughran SJ; Di Rago L; Kile BT; Alexander WS
    Blood; 2010 May; 115(19):3966-9. PubMed ID: 20007548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondrial dysfunction and tau hyperphosphorylation in Ts1Cje, a mouse model for Down syndrome.
    Shukkur EA; Shimohata A; Akagi T; Yu W; Yamaguchi M; Murayama M; Chui D; Takeuchi T; Amano K; Subramhanya KH; Hashikawa T; Sago H; Epstein CJ; Takashima A; Yamakawa K
    Hum Mol Genet; 2006 Sep; 15(18):2752-62. PubMed ID: 16891409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype-phenotype relationships.
    Belichenko PV; Kleschevnikov AM; Salehi A; Epstein CJ; Mobley WC
    J Comp Neurol; 2007 Oct; 504(4):329-45. PubMed ID: 17663443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired Ca-signaling in astrocytes from the Ts16 mouse model of Down syndrome.
    Müller W; Heinemann U; Schuchmann S
    Neurosci Lett; 1997 Feb; 223(2):81-4. PubMed ID: 9089678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A smaller olfactory bulb in a mouse model of Down syndrome.
    Bontempi P; Cisterna B; Malatesta M; Nicolato E; Mucignat-Caretta C; Zancanaro C
    Acta Neurobiol Exp (Wars); 2020; 80(4):375-380. PubMed ID: 33350990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosage-dependent over-expression of genes in the trisomic region of Ts1Cje mouse model for Down syndrome.
    Amano K; Sago H; Uchikawa C; Suzuki T; Kotliarova SE; Nukina N; Epstein CJ; Yamakawa K
    Hum Mol Genet; 2004 Jul; 13(13):1333-40. PubMed ID: 15138197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.